The vaccinal prophylaxis of hepatitis B among children born to mothers with persistent HBs-antigenemia
Khukhlovich, P.A.; Shakhgil'dian, I.V.; Narkevich, M.I.; Anan'ev, V.A.; Kuzin, S.N.; Sergeeva, N.A.; Khodzhaev, S.K.; Iarovoĭ, P.I.; Drobeniuk, Z.A.; Iuldashev, A.K.; Khodzhaeva, M.A.; Makmudova, O.N.; Buriev, A.I.; Rakhimov, R.A.; Tuliaganova, G.M.; Khasanova, V.A.; Tsvaĭner, M.I.; Eliseeva, T.S.; Tuĭchibaeva, M.A.; Mineecheva, L.V.; Kotsaga, E.I.; Nagachevskaia, V.I.; Rafikova, N.K.; Klimenko, S.M.
Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 2: 55-59
1996
ISSN/ISBN: 0372-9311 PMID: 8701658 Document Number: 460837
In Uzbekistan and Moldova 542 children born of HBsAg carriers were immunized against hepatitis B (with vaccine Engerix B according to the immunization schedule of 4 injections). Anti-HBs antibodies in protective titers were detected by EIA and RIA techniques in 76.7% of children aged 4-5 months after the 3rd injection, in 95.7% of children aged 15-16 months and in 90.0% of children aged 2-2.5 years after the 4th (booster) injection. In the control group (117 nonimmunized children born of HBs carriers) observed during the same period anti-HBs antibodies were detected significantly less frequently (in 7.3%, 11.6% and 12.9% of these children respectively). 1-2 months after the course of immunization was completed 74.1% of the immunized children had high anti-HBs antibody titers (exceeding 1000 IU/ml) with their subsequent decrease by 2-2.5 years of age. In the control group these figures were 27.1% and 29.0% respectively. The index of immunization effectiveness obtained by the comparison of the hepatitis B morbidity rates in both groups was 7.8. No postvaccinal complications were registered.